[{"abstract": "A merger would create a drug giant with nearly $53 billion in annual sales and give Pfizer a long-sought foreign headquarters for tax purposes.", "web_url": "https://www.nytimes.com/2015/11/19/business/dealbook/pfizer-allergan-deal-for-up-to-150-billion-is-said-to-be-close-to-complete.html", "snippet": "A merger would create a drug giant with nearly $53 billion in annual sales and give Pfizer a long-sought foreign headquarters for tax purposes.", "lead_paragraph": "Pfizer is nearing a deal to buy Allergan, a rival drug maker that has its headquarters in Ireland, for as much as $150 billion, potentially helping the company move its corporate citizenship abroad and reduce its tax bill, a person briefed on the matter said on Wednesday.", "print_section": "B", "print_page": "6", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/20/business/db-drug-web1/db-drug-web1-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/11/20/business/db-drug-web1/db-drug-web1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/20/business/db-drug-web1/db-drug-web1-jumbo.jpg", "height": 683, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/20/business/db-drug-web1/db-drug-web1-superJumbo.jpg", "height": 1366, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/20/business/db-drug-web1/db-drug-web1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/11/20/business/db-drug-web1/db-drug-web1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/20/business/db-drug-web1/db-drug-web1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer and Allergan Said to Be Near Merger for Up to $150 Billion", "kicker": null, "content_kicker": null, "print_headline": "Pfizer and Allergan Said to Be Close to $150 Billion Merger", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "ALLERGAN INC", "rank": 1, "major": "N"}, {"name": "persons", "value": "de la Merced, Michael J", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 3, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 4, "major": "N"}, {"name": "subject", "value": "Tax Shelters", "rank": 5, "major": "N"}, {"name": "subject", "value": "Corporate Taxes", "rank": 6, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 7, "major": "N"}], "pub_date": "2015-11-19T01:50:50+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Michael J. de la Merced", "person": [{"firstname": "Michael", "middlename": "J.", "lastname": "de la Merced", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/f9b5103b-f147-5063-9b41-e845f7b9ea56", "word_count": 580, "uri": "nyt://article/f9b5103b-f147-5063-9b41-e845f7b9ea56"}, {"abstract": "Buying Allergan would give the drug giant a low-tax domicile in Ireland and one good drug, Botox. But Allergan would accrue nearly all of the upside.", "web_url": "https://www.nytimes.com/2015/11/20/business/dealbook/high-risk-and-low-benefit-in-pfizers-pursuit-of-allergan.html", "snippet": "Buying Allergan would give the drug giant a low-tax domicile in Ireland and one good drug, Botox. But Allergan would accrue nearly all of the upside.", "lead_paragraph": "Pfizer\u2019s $150 billion Botox gamble is a high-risk, low-benefit deal.", "source": "The New York Times", "multimedia": [], "headline": {"main": "High Risk and Low Benefit in Pfizer\u2019s Pursuit of Allergan", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 3, "major": "N"}, {"name": "subject", "value": "Federal Taxes (US)", "rank": 4, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 5, "major": "N"}, {"name": "persons", "value": "Read, Ian C", "rank": 6, "major": "N"}], "pub_date": "2015-11-19T19:12:32+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/09141cb3-72e2-5666-a4f6-4d41be980422", "word_count": 389, "uri": "nyt://article/09141cb3-72e2-5666-a4f6-4d41be980422"}]